Despite the success of BCR-ABL tyrosine kinase inhibitor (e.g., imatinib) results in complete cytogenetic response in most cases of chronic-phase CML, but results in poor responses in advanced phases of the disease, with frequent relapse [3]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.